The next frontier in obesity drugs: lasting weight loss
Introducing Fierce Biotech’s 2026 Fierce 15
Alveus Therapeutics Initiates Phase 2 PRESERVE Trial to Evaluate ALV-100 for Chronic Weight Management
Alveus Therapeutics taps Novo Nordisk veteran for executive role
Alveus Therapeutics Strengthens Executive Leadership Team, Opens Boston office
Alveus: Best-in-class opportunity in obesity
Obesity company closes capital raising of DKK 1.2 billion – brings Novo Holdings on board
Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases
Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next-Generation Therapies for Obesity and Metabolic Diseases
Han forlod Novo for at bygge nyt fedmeselskab op fra bunden: “I sidste ende føles det helt rigtigt”
Equipped with $160M series A, Alveus debuts into crowded obesity development landscape
Parabilis Heads Biotech Fundraising Frenzy With $305M to Advance Cancer Drug
Obesity biotech Alveus gains $160M for push into MariTide’s backyard — and amylins
Alveus Therapeutics exits stealth with $160M, developing an alternative to drugs like Ozempic
$160 million Series A round for Alveus
Alveus Therapeutics Announces FDA Clearance of IND and First Patient Dosed in Phase 1b Trial of ALV-100 for Obesity
Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases
Biotech Alveus raises $160 million to tackle weight loss maintenance
Alveus raises $160M Series A for obesity drugs
Philadelphia VC firm creates obesity drug startup, raises $159.8M Series A
Alveus Therapeutics, a Philadelphia start-up treating obesity, debuted with $160M in funding
Alveus launches with $160M as newest start-up to step into obesity fray